OBJECTIVES The aim of this study was to assess the incidence and clinical impact of balloon post-dilation (BPD) after transcatheter aortic valve replacement (TAVR) with the CoreValve prosthesis (Medtronic Inc., Minneapolis, Minnesota).
T ranscatheter aortic valve replacement (TAVR)
has matured into a viable treatment alternative for patients with severe aortic stenosis at high-risk of conventional surgical aortic valve replacement (1, 2) . Although associated with excellent hemodynamic results, residual paravalvular regurgitation (PVR) occurs frequently with this procedure, having been reported in 80% to 96% of TAVR cases (3) . Moderate or severe PVR occurs in w10% to 15% of procedures, and this was observed to produce significantly worse outcomes (2, 3) .
Balloon post-dilation (BPD) has been shown to be a feasible and effective strategy to reduce significant PVR by enabling better expansion of the stent frame containing the biological valve and thus improved sealing (4) . However, this technique is ineffective when PVR is caused by a "too high" or "too low" implantation, and some argue that post-dilation itself may potentially increase the risk of iatrogenic cerebrovascular events (5, 6) . However, these latter observations come from a few single-center studies with relatively small populations. The aim of this large multicenter analysis was to evaluate the prevalence of BPD after TAVR with a self-expanding prosthesis and its relative impact on clinical outcomes. were compared using the Mann-Whitney nonparametric test. Differences in proportions were compared by applying a chi-square analysis. Time to long-term outcomes was described by means of the Kaplan-Meier curve and compared between groups by means of the log-rank test.
After testing for proportional hazard assumptions, Cox models were fitted considering all variables from Tables 1 and 2 Main procedural variables are presented in Table 2 .
The transfemoral approach was the most frequently used (81.1%), followed by the transsubclavian (14.4%) and transaortic (4.5%) approaches, with no differences between the 2 groups (p ¼ 0.996). BPD was more frequently performed when the 29-mm (54.6% vs. 43.4%) and the 31-mm (12.9% vs. 5.0%) prostheses were implanted (p < 0.001) and when a second CoreValve was required as a bailout procedure for acute implant failure (14.0% vs. 2.7%; p < 0.001).
The balloon sizes used for BPD for each THV size are listed in the Table 3 . Neither valve embolization nor aortic root injury and coronary occlusion occurred during BPD. There were no statistically significant differences between the 2 groups in the incidence of in-hospital all-cause and cardiovascular mortality, neurological events, myocardial infarction, bleeding,
and conversion to open-chest surgery. Of note, a trend toward a higher rate of high-degree conduction disturbances requiring permanent pacemaker Values are % (n/N) or n (range).
BPD ¼ balloon post-dilation. implantation was reported in the BPD group, whereas a statistically significant higher rate of left bundle branch block was reported in the no-BPD group (26.1% vs. 32.6%; p ¼ 0.038) ( Table 4) On echocardiography, no differences in terms of residual transprosthetic gradient were reported in the 2 groups, whereas residual PVR more than mild was still more frequently observed in the BPD group (37.9% vs. 17.1%; p < 0.001). or "too high" implant, as well as the deployment of an undersized THV, any attempt at further frame dilation is generally futile (12) . In these cases, the best options to decrease the degree of PVR is to implant a second prosthesis in a Valve-in-Valve fashion (14) or, in the case of the CoreValve device, Tables 1, 4 , and 5.
Abbreviations as in

CONCLUSIONS
This large multicenter analysis showed that BPD was ineffective at reducing PVR after TAVR with the self-expanding CoreValve in 37% of cases. This strategy was safe and was not associated with increased cerebrovascular events, mortality, myocardial infarction, and aortic root injury rates.
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